Does Semaglutide Suppress Appetite Immediately — or Does It Take Time?

Why doesn't the appetite effect kick in straight away?

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone that slows the movement of food out of the stomach, signals to the hypothalamus that you have eaten enough, and reduces the drive to seek food between meals. These are real biological effects, and they begin from the first injection. The problem is that the starting dose is deliberately low, set at 0.25mg for Wegovy, because starting higher causes more nausea, vomiting and dizziness than most people are willing to tolerate.

At 0.25mg, the GLP-1 signal is present but modest. Gastric emptying slows a little; some people do notice slightly smaller portion sizes feeling more satisfying. But the pronounced appetite dampening that clinical trials measured (and that many people starting treatment are hoping for) tends to emerge at higher doses, typically from around 1mg upward. The timeline for when semaglutide starts suppressing appetite is shaped almost entirely by how quickly the dose can be increased, which the prescriber controls based on tolerability.

This gradual approach is not a flaw in the treatment. It is the reason most people are able to stick with it long enough to see the full effect. You can read more about the broader picture on the Wegovy overview page.

What does the clinical trial evidence actually show about timing?

The STEP 1 trial, published in the New England Journal of Medicine, followed adults on semaglutide 2.4mg over 68 weeks and found an average body-weight reduction of around 15% compared with placebo. That figure reflects the maintenance dose, the one participants reached after roughly 16 weeks of gradual titration. It does not describe what happened in week one.

In practice, trial participants reported reduced hunger and greater fullness ratings increasing over the first several months, broadly tracking dose increases. The question of how soon Wegovy suppresses appetite is therefore best answered dose-by-dose rather than as a single date. For many participants, the effect became subjectively noticeable somewhere between the 0.5mg and 1.0mg stages, though this varies considerably between individuals. Some people describe a clear shift in their relationship with food by week four or five; others reach 1.7mg before feeling a meaningful difference. According to NHS guidance on semaglutide, common side effects including nausea tend to settle within days to a couple of weeks, which is worth knowing because early nausea can feel like it IS the appetite suppression, when in fact they are separate phenomena.

Does semaglutide do anything beyond reducing hunger?

A question worth asking early in treatment. Reduced appetite is the most obvious experience, but it is not the only mechanism driving weight loss on semaglutide. Slower gastric emptying means meals sit with you longer, which on its own reduces calorie intake even if the brain's hunger signal has not shifted dramatically yet. There is also emerging evidence around changes in food preference and reduced cravings for high-fat, highly processed foods, though this is an area of active research rather than settled fact.

What this means practically is that even if the big appetite drop has not arrived yet, eating behaviour may already be shifting in subtler ways. Many people find that what they eat on Wegovy starts to change before they consciously notice feeling less hungry. Protein intake, meal timing and avoiding eating through nausea all interact with how well the medicine works. The page on what Wegovy does beyond appetite suppression covers the wider picture in more detail.

For context on how the cost of private treatment compares with what is available on the NHS, the Wegovy price comparison page sets that out plainly.

What should you do if you reach 1mg and still feel no difference?

This is genuinely one of the questions our prescribers hear most often. The short answer is: tell your prescriber, rather than drawing conclusions alone. A small proportion of people do have a blunted subjective experience of appetite suppression even at higher doses, while still losing weight measurably. Others find the effect appears suddenly at a particular dose after weeks of feeling nothing had changed, especially if early nausea had been masking the underlying shift in hunger.

There are also lifestyle factors that can dilute the appetite effect: very high-calorie liquid meals pass the stomach quickly regardless of how much semaglutide slows it; eating at irregular times makes it harder to notice fullness cues; poor sleep increases ghrelin independently of what semaglutide is doing. Reading about intermittent fasting alongside Wegovy may be useful if you are thinking about meal-timing approaches, though any change to eating patterns on treatment should be discussed with your clinical team first.

If you are not yet on semaglutide and are considering it, the free consultation with nume's prescribers is the place to start, you can check your eligibility and ask these questions before committing to anything.